BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing

Journal of Medical Genetics

Volumn 41, Issue 9, 2004, Pages 664-668

  Domingo, E ^a   Laiho, P ^b   Ollikainen, M ^b   Pinto, M ^c   Wang, L ^d   French, A J ^d   Westra, J ^e   Frebourg, T ^f   Espin E ^a   Armengol, M ^a   Hamelin, R ^g   Yamamoto, H ^h   Hofstra, R M W ^d   Seruca, R ^c   Lindblom, A ⁱ   Peltomaki P ^b   Thibodeau, S N ^d   Aaltonen, L A ^b   Schwartz Jr , S ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF PORTO   (Portugal)

^d MAYO CLINIC   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g FONDATION JEAN DAUSSET CEPH   (France)

^h SAPPORO MEDICAL UNIVERSITY   (Japan)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MLH1; PROTEIN MSH2;

ARTICLE; CANCER SCREENING; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE BRAF; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; GENETIC SCREENING; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 4444311092     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.020651     Document Type: Article

References (33)

1. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.
2. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-61.
3. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
4. Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Nystrom-Lahti M, Seruca R, David L, Holm R, Ryberg D, Haugen A. Microsatellite instability is associated with tumours that characterise the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 1993;53:5853-5.
5. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
6. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999;36:801-18.
7. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995;87:1114-25.
8. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271-2.
9. Vasen HFA, Mecklin J-P, Khan PM, Lynch HT. The international collaborative group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.
10. Vasen HFA, Watson P, Mecklin J-P, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 1999;116:1453-6.
11. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S. A National Cancer Institute workshop on hereditary colorectal cancer syndrome: meeting highlights and Bethesda Guidelines. J Natl Cancer Inst 1997;89:1758-62.
12. Nyström-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA, Moisio AL, Jarvinen HJ, Mecklin JP, Kinzler KW, Vogelstein B. Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med 1995;1:1203-6.
13. Ramsey SD, Clarke L, Tzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001;135:577-88.
14. Reyes CM, Allen BA, Terdiman JP, Wilson LS. Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness. Cancer 2002;95:1848-50.
15. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumours and mismatch repair defective human tumor cell lines. Cancer Res 1997;57:808-11.
16. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Morkowitz SD. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998;95:8698-702.
17. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, Horkonen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Jarvinen H, Mecklin JP, Aaltonen LA, de la Chapelle A. Population-based molecular detection of hereditary nonpolyposis colorectal cancer [correction appeared in J Clin Oncol 2000;18:3456]. J Clin Oncol 2000;18:2193-200.
18. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003;22:9217-24.
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
20. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
21. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-12.
22. Domingo E, Espin E, Armengol M, Oliveira C, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H, Schwartz S Jr. Activated BRAF targets proximal colon tumours with mismatch repair deficiency and hMLH1 inactivation. Genes Chromosomes Cancer 2004;39:138-42.
23. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B, Sleisenger MH, Kim YS. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-5.
24. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava SA. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsotellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
25. Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 1997;57:300-3.
26. Di Fiore F, Charbonnier F, Martin C, Frerat S, Olschwang S, Wang Q, Boisson C, Buisine MP, Nilbert M, Lindblom A, Frebourg T. Screening for genomic rearrangements of the MMR genes must be included in the routine diagnosis of HNPCC. J Med Genet 2004;41:18-20.
27. Gille JJ, Hogervorst FB, Pals G, Wijnen JT, van Schooten RJ, Dommering CJ, Meijer GA, Craanen ME, Nederlof PM, de Jong D, McElgunn CJ, Schouten JP, Menko FH. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 2002;87:892-7.
28. Wahlberg S, Liu T, Lindblom P, Lindblom A. Various mutation screening techniques in the DNA mismatch repair genes hMSH2 and hMLH1. Genet Test 1999;3:259-64.
29. Cunningham JM, Kim C-Y, Christensen ER, Tester DJ, Parc Y, Burgart LJ, Hailing KC, McDonnell SK, Schaid DJ, Walsh Vockley C, Kubly V, Nelson H, Michels VV, Thibodeau SN. The frequency of hereditary defective mismatch repair in a prospective series of unselectea colorectal carcinomas. Am J Hum Genet 2001;69:780-90.
30. American Cancer Society. Cancer facts and figures 1999. Atlanta: American Cancer Society, 1999.
31. Vasen HF, Mecklin J-P, Watson P, Utsunomiya J, Bertario L, Lynch P, Svendsen LB, Cristofaro G, Muller H, Meera Khan P, Lynch HT (The International Collaborative Group on HNPCC). Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study on 165 families. Dis Colon Rectum 1993;36:1-4.
32. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
33. Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC, Ducreux M, Praz F. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003;63:5738-44.